Cost-effectiveness of clopidogrel plus aspirin vs. aspirin alone for secondary-prevention of cardiovascular events: Results from the CHARISMA trial

被引：0

作者：

Chen, Jersey

Bhatt, Deepak L.

Schneider, Elizabeth

Shi, Chunxue

Caro, Jaime

Proskorovsky, Irina

Hacke, Werner

Fox, Keith A.

Cohen, David J.

机构：

[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[2] Cleveland Clin, Cleveland, OH 44106 USA

[3] Harvard Clin Res Inst, Boston, MA USA

[4] Caro Res, Concord, MA USA

[5] Univ Heidelberg, D-6900 Heidelberg, Germany

[6] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland

来源：

CIRCULATION | 2006年 / 114卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：826 / 826

页数：1

共 50 条

[31] Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
Bhatt, DL
Topol, EJ
[J]. AMERICAN HEART JOURNAL, 2004, 148 (02) : 263 - 268
[32] Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective
Ademi, Zanfina
Zomer, Ella
Tonkin, Andrew
Liew, Danny
[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 270 : 54 - 59
[33] COST-EFFECTIVENESS OF RIVAROXABAN AND ASPIRIN COMPARED TO ASPIRIN ALONE IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE: AN AUSTRALIAN PERSPECTIVE
Ademi, Z.
Zomer, E.
Tonkin, A.
Liew, D.
[J]. VALUE IN HEALTH, 2018, 21 : S2 - S2
[34] COST-EFFECTIVENESS OF ASPIRIN IN SECONDARY PREVENTION OF CORONARY HEART-DISEASE
GASPOZ, JM
GOLDMAN, P
WILLIAMS, L
WEINSTEIN, M
GOLDMAN, L
[J]. CIRCULATION, 1995, 92 (08) : 219 - 219
[35] High-risk acute coronary syndromes: cost-effectiveness of clopidogrel plus aspirin
[J]. Nature Clinical Practice Cardiovascular Medicine, 2005, 2 (5): : 229 - 230
[36] An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients in Italy
Rudelli, G
Annemans, L
Spiesser, J
Novelli, M
Walker, A
Gabriel, S
[J]. VALUE IN HEALTH, 2004, 7 (06) : 686 - 687
[37] Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Gaspoz, J
Coxson, PG
Goldman, PA
Williams, LW
Kuntz, KM
Hunink, MGM
Goldman, L
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23): : 1800 - 1806
[38] Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness
Ho, WK
Hankey, GJ
Eikelboom, JW
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (03) : 493 - 503
[39] Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
Ferrara, Pietro
Cortesi, Paolo A.
Di Laura, Danilo
Maggioni, Aldo P.
Mantovani, Lorenzo G.
[J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (05) : 459 - 468
[40] Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
Pietro Ferrara
Paolo A. Cortesi
Danilo Di Laura
Aldo P. Maggioni
Lorenzo G. Mantovani
[J]. Clinical Drug Investigation, 2021, 41 : 459 - 468

← 1 2 3 4 5 →